Defunct Company
Total Trials
11
As Lead Sponsor
10
As Collaborator
1
Total Enrollment
2,526
NCT04783766
Safety, Tolerability and Pharmacokinetics Study of CK-3773274
Phase: Phase 1
Role: Lead Sponsor
Start: Apr 10, 2021
Completion: Aug 5, 2021
NCT05186818
Aficamten vs Placebo in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM)
Phase: Phase 3
Role: Collaborator
Start: Feb 1, 2022
Completion: Dec 18, 2023
NCT05410860
Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia
Start: Jun 30, 2022
Completion: Dec 10, 2024
NCT05378945
Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease
Start: Jul 22, 2022
Completion: Apr 4, 2023
NCT05576415
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of OC-01 in Adult Chinese With Dry Eye Disease
Start: Dec 7, 2022
Completion: Apr 27, 2023
NCT05511870
A Study of Etripamil in Healthy Subjects
Start: Mar 7, 2023
Completion: Mar 26, 2023
NCT06045299
Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia
Start: Sep 27, 2023
Completion: Jan 27, 2025
NCT06116968
An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM
Start: Nov 14, 2023
Completion: Mar 15, 2026
NCT06270030
Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Chinese With Presbyopia
Start: Mar 4, 2024
Completion: Apr 10, 2024
NCT06990867
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
Phase: Phase 2/3
Start: May 15, 2025
Completion: Dec 31, 2029
NCT07011797
A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants
Phase: Phase 2
Start: Jun 17, 2025
Completion: Apr 6, 2026